The estimated Net Worth of Judith L Swain is at least $179 mil dollars as of 28 April 2024. Judith Swain owns over 8,032 units of Lexicon Pharmaceuticals Inc stock worth over $81,735 and over the last 17 years he sold LXRX stock worth over $0. In addition, he makes $96,865 as Independent Director at Lexicon Pharmaceuticals Inc.
Sign up
Judith Swain LXRX stock SEC Form 4 insiders trading
Judith has made over 5 trades of the Lexicon Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 8,032 units of LXRX stock worth $13,574 on 28 April 2024.
The largest trade he's ever made was exercising 10,638 units of Lexicon Pharmaceuticals Inc stock on 24 April 2021 worth over $17,978. On average, Judith trades about 1,542 units every 64 days since 2007. As of 28 April 2024 he still owns at least 48,364 units of Lexicon Pharmaceuticals Inc stock.
You can see the complete history of Judith Swain stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Judith Swain biography
Dr. Judith L. Swain M.D. serves as Independent Director of the Company. Dr. Swain has been a director since September 2007. Dr. Swain is a visiting professor of medicine at the National University of Singapore and chief medical officer of Physiowave, Inc. She previously served as founding director of the Singapore Institute for Clinical Sciences, dean for translational medicine at the University of California, San Diego, chair of the Department of Medicine at Stanford University, and on the medical faculties of the University of Pennsylvania and Duke University. She has previously served in a number of national and international leadership roles and as a director or member of the scientific advisory boards for a number of biomedical technology companies and is co-founder of Synecor, LLC. Dr. Swain received her B.S. from the University of California, Los Angeles and her M.D. from the University of California, San Diego.
What is the salary of Judith Swain?
As the Independent Director of Lexicon Pharmaceuticals Inc, the total compensation of Judith Swain at Lexicon Pharmaceuticals Inc is $96,865. There are 13 executives at Lexicon Pharmaceuticals Inc getting paid more, with Lonnel Coats having the highest compensation of $3,870,290.
How old is Judith Swain?
Judith Swain is 71, he's been the Independent Director of Lexicon Pharmaceuticals Inc since 2007. There are 4 older and 15 younger executives at Lexicon Pharmaceuticals Inc. The oldest executive at Lexicon Pharmaceuticals Inc is Alan Nies, 82, who is the Independent Director.
What's Judith Swain's mailing address?
Judith's mailing address filed with the SEC is 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS, TX, 77381.
Insiders trading at Lexicon Pharmaceuticals Inc
Over the last 17 years, insiders at Lexicon Pharmaceuticals Inc have traded over $161,951 worth of Lexicon Pharmaceuticals Inc stock and bought 392,158,422 units worth $731,672,961 . The most active insiders traders include International S.C.A.Minne P..., International S.C.A.Wittouc... y Llc Invus, L.P.Invus Adviso.... On average, Lexicon Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $5,348,701. The most recent stock trade was executed by International S.C.A.Wittouc... on 10 May 2024, trading 57,546,100 units of LXRX stock currently worth $97,252,909.
What does Lexicon Pharmaceuticals Inc do?
corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio
What does Lexicon Pharmaceuticals Inc's logo look like?
Complete history of Judith Swain stock trades at Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc executives and stock owners
Lexicon Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Lonnel Coats,
President, Chief Executive Officer, Director -
Praveen Tyle,
Executive Vice President - Research and Development -
Jeffrey Wade,
Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs -
Lonnel Coats,
CEO & Director -
Alan Main,
Executive Vice President, Commercial Supply Operations -
Jeffrey L. Wade J.D.,
Pres & CFO -
Dr. Alan J. Main Ph.D.,
Exec. VP of Innovation & Chemical Sciences -
Dr. Alan J. Main,
Exec. VP of Innovation & Chemical Sciences -
Brian T. Crum,
VP, Gen. Counsel & Sec. -
James Tessmer,
Vice President - Finance and Accounting -
Raymond Debbane,
Independent Chairman of the Board -
Samuel Barker,
Independent Director -
Frank Palantoni,
Independent Director -
Judith Swain,
Independent Director -
Philippe Amouyal,
Independent Director -
Robert Lefkowitz,
Independent Director -
Christopher Sobecki,
Independent Director -
Alan Nies,
Independent Director -
Dr. Robert J. Lefkowitz,
Consultant & Independent Director -
Brian Crum,
Vice President, General Counsel -
Dr. Craig B. Granowitz M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Kristen L. Alexander,
VP of Fin. & Accounting -
Chas Schultz,
Exec. Director of Corp. Communications & Patient Advocacy -
Sam L Barker,
Director -
Alexander A Santini,
EVP and CCO -
Pablo Lapuerta,
EVP and CMO -
International S.C.A.Wittouc...,
-
Us Partners Llc Ulys, L.L.C...,
-
Tamar D Howson,
EVP of Bus Dev -
Barry Mills,
Director -
Julia P Gregory,
EVP and CFO -
James R Phd Piggott,
SVP of Pharm Bio -
Lance K Ishimoto,
SVP, Intellectual Property -
Clayton Stuart Rose,
Director -
Public Equities, L.P.Artal ...,
-
Public Equities, L.P.Artal ...,
-
International S.C.A.Minne P...,
-
Diane E. Sullivan,
Director -
Thomas Garner,
SVP, Chief Commercial Officer -
Arthur T Sands,
Pres & CEO -
John Northcott,
VP, Marketing, Comm Strategy -
Cv Ulys, L.L.C.Debbane Raym...,
-
International S.C.A.Minne P...,
-
Brian P Zambrowicz,
EVP, Chief Scientific Officer -
Llc Invus, L.P.Invus Public...,
-
International S.C.A.Invus, ...,
-
Kathleen M Wiltsey,
Director -
Llc Invus, L.P.Invus Adviso...,
-
Philip M Brown,
SVP Clinical Development -
Steven Alan Tragash,
VP, Corporate Affairs -
Llc Invus, L.P.Invus Adviso...,
-
Ajay Bansal,
EVP Corp Dev and CFO -
Kristen Alexander,
VP, Finance and Accounting -
C.V. Invus,
Director -
Craig B Granowitz,
SVP, Chief Medical Officer -
Kenneth B. Kassler Taub,
SVP, Regulatory & QA -
Wendy Mc Dermott,
VP, Human Resources -
Kiernan Seth,
VP, Chief Commercial Officer -
Michael Exton,
Chief Executive Officer -
Brian Corrigan,
SVP, Regulatory & QA